QIAGEN is New Lab Partner for SmiLe Venture Hub

QIAcuity, a digital PCR (dPCR) instrument, now at SmiLe's lab.

We are excited to announce our latest lab partnership collaboration with QIAGEN, a leading provider of cutting-edge laboratory instruments. Through this partnership, QIAGEN has generously equipped our laboratories with its advanced QIAcuity, a digital PCR (dPCR) instrument.

As part of SmiLe's strategy to provide a wide range of services to our member companies, the partnership program is a key cornerstone. One part of this program is to offer easy access to state-of-the-art laboratory instrumentation at our labs, not only to our members but also to companies outside our community through the Open Lab South program.

With the addition of QIAGENs state-of-the-art QIAcuity instrument to our labs, new opportunities open for companies working in life sciences, offering a possibility to enhance product development through precise nucleic acid detection.

The dPCR technology brings new levels of sensitivity and precision in nucleic acid detection and quantification, enabling more accurate and reliable measurements. With the QIAcuity instrument, companies can now conduct both small and large studies using this groundbreaking technology. Digital PCR delivers absolute quantification without the need for a standard curve. It also offers improved reproducibility compared to traditional quantitative PCR, along with simultaneous quantification of multiple genetic targets.

"This strategic partnership gives us the opportunity to let more companies experience the full range of benefits and possibilities that dPCR technology can offer. SmiLes dynamic community of biotech startups, situated in one of Swedens largest life science hubs, provides the ideal setting for placing our dPCR instrument where advanced scientific challenges can be addressed. We are very excited to be here," says Peter Magnusson, Senior Account Manager at QIAGEN.

In addition to providing the instrument, QIAGEN will also offer expert support to guide new users through their scientific analyses and ensure they can fully leverage the potential of the dPCR platform.

"At SmiLe, we are always working to enhance our lab facilities to offer the very best instruments to our members. Through our strategic partnership with QIAGEN, we are excited to offer our community of companies the opportunity to take their development work to new levels. Transitioning from quantitative PCR to digital PCR allows researchers to access and analyze data that was previously difficult to resolve with qPCR," says Ulrika Ringdahl, COO of SmiLe.